Open access
Aug 2026
Diagnostic regulatory pathways are an underrecognized bottleneck in precision oncology clinical trials: Real-world evidence across Europe.
Biomarker strategies and diagnostic testing approaches should be thoughtfully constructed and considered pragmatically, as inefficient implementation may directly affect trial interpretability, efficacy assessment and regulatory success, substantially compromising trial delivery in Europe.
Sarah Hersey, Haydar Çelik, Steven T. Rosen et al.
· European Journal of Cancer · 0 citations